Target Customers’ Profile 30% Sub-fertile 70% Birth control 100% Cervical health cancer, STDs Three statistics tell the story Personalized medicine - diagnostic tools $232 Billion personalized medicine market to grow 11% annually said PricewaterhouseCoopers
70% of women “would switch” 70% of women who would buy the Ovulona Smart Sensor, would switch from their current birth control to our fertility status monitor [from a survey of 5,000 US women]
Cervical Cancer Screen Innocuous affordable triage for colposcopy-biopsy As the sensor monitors cervical tissues, other STIs will have specific signatures. Through the HPO axis, other gynecological cancers may become detectable. Billions women globally. Tens of millions reproductive-age women in the U.S. alone. This screen is for everyone. Affordable. Private. Solid.
Friendly Technology From Home to Healthcare Providers From patients’ Ovulona™ units to physician’s Ovulograph™ – when needed
Applications, apps Helping to Conceive Pregnancy Managing Menstrual Cycle Natural Birth Control Managing Menopause Cervical Cancer, STD Screening
Total Available Market 09/02/11 bioZhena Corporation Cervical cancer screening is an estimated annual $5B US Pap smear test market. Worldwide extrapolation: >$100B annually. Ovulona™ will save an est. 50% - 90%. Segments of bioZhena’s target market: Trying to Conceive Pregnancy Market Managing Menstrual Cycle Market Birth Control Market Managing Menopause Market Cervical Health Screening Market U.S. ~$ 25B World >$500B
bioZhena Corporation’s Offering Personalized Health Management Contact firstname.lastname@example.org